Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Spectrochim Acta A Mol Biomol Spectrosc ; 312: 124008, 2024 May 05.
Article in English | MEDLINE | ID: mdl-38364449

ABSTRACT

In the minerals processing industry, the surface chemistry of mineral particles and its real-time detection can significantly enhance process performance, and ultimately leading to automotive and intelligent control. The adsorption of collector molecule onto bulk mineral specimens could be investigated with the help of shell-isolated nanoparticle enhanced Raman spectroscopy (SHINERS). However, this method is unsuitable for the online detection of particles fluid consisted of micro-sized chalcocite that encountered in industrial production processes. In this work, a novel strategy of shell-isolated nanoparticles synthesis by electrodeposition of gold nanoparticles film and isolation of this film with crosslinked silica monolayer was proposed. The adsorption of 2-mercaptobenzothiazole (MBT), a typical flotation collector, onto a copper sulfide mineral, chalcocite was measured in-situ with the help of such a SERS substrate. Enhancement factors of 106-107 was calculated based on an idealized model. Furthermore, we discussed the stability of the silica isolation monolayer under high-power laser irradiation.

2.
J Hepatocell Carcinoma ; 10: 599-609, 2023.
Article in English | MEDLINE | ID: mdl-37069959

ABSTRACT

Objective: Pre-S1 antigen (pre-S1) is a component of hepatitis B virus large surface antigen (L-HBsAg). This study aimed to investigate the association between clinical pre-S1 antigen (pre-S1) status and adverse prognostic events in chronic hepatitis B (CHB) patients. Methods: This study retrospectively enrolled 840 CHB patients with comprehensive clinical data, including 144 patients with multiple follow-up of pre-S1 status. All patients were tested for serum pre-S1 and divided into pre-S1 positive and negative groups. Single factor and logistic multiple regression analyses were performed to explore the association between pre-S1 and other HBV biomarkers with the risk of hepatocellular carcinoma (HCC) in CHB patients. The pre-S1 region sequences of HBV DNA were obtained from one pre-S1 positive and two pre-S1 negative treatment-naïve patients using polymerase chain reaction (PCR) amplification followed by Sanger sequencing. Results: The quantitative HBsAg level was significantly higher in the pre-S1 positive group than that in the pre-S1 negative group (Z=-15.983, P<0.001). The positive rate of pre-S1 increased significantly with the increase in HBsAg level (χ 2=317.963, P<0.001) and HBV DNA load (χ 2=15.745, P<0.001). The pre-S1 negative group had a higher HCC risk than the pre-S1 positive group (Z=-2.00, P=0.045, OR=1.61). Moreover, patients in the sustained pre-S1 negative group had a higher HCC risk (Z=-2.56, P=0.011, OR=7.12) than those in the sustained pre-S1 positive group. The sequencing results revealed mutations in the pre-S1 region from samples of pre-S1 negative patients, including frameshift and deletion mutations. Conclusion: Pre-S1 is a biomarker that indicates the presence and replication of HBV. Pre-S1 sustained negativity attributed to pre-S1 mutations in CHB patients may be associated with a higher risk of HCC, which has clinical significance and warrant further investigations.

3.
World J Clin Cases ; 10(8): 2369-2381, 2022 Mar 16.
Article in English | MEDLINE | ID: mdl-35434070

ABSTRACT

In recent years, marine-derived bioactive compounds have gained increasing attention because of their higher biodiversity vs land-derived compounds. A number of marine-derived compounds are proven to improve lipid metabolism, modulate the gut microbiota, and possess anti-inflammatory, antioxidant, antibacterial, antiviral, and antitumor activities. With the increasing understanding of the molecular landscape underlying the pathogenesis of chronic liver diseases, interest has spiked in developing new therapeutic drugs and medicine food homology from marine sources for the prevention and treatment of liver diseases.

4.
J Cell Mol Med ; 25(2): 867-879, 2021 01.
Article in English | MEDLINE | ID: mdl-33269546

ABSTRACT

Liver fibrogenesis is a complex scar-forming process in the liver. We suggested that the liver first responded to chronic injuries with gradual changes, then reached the critical state and ultimately resulted in cirrhosis rapidly. This study aimed to identify the tipping point and key molecules driving liver fibrosis progression. Mice model of liver fibrosis was induced by thioacetamide (TAA), and liver tissues were collected at different time-points post-TAA administration. By dynamic network biomarker (DNB) analysis on the time series of liver transcriptomes, the week 9 post-TAA treatment (pathologically relevant to bridging fibrosis) was identified as the tipping point just before the significant fibrosis transition, with 153 DNB genes as key driving factors. The DNB genes were functionally enriched in fibrosis-associated pathways, in particular, in the top-ranked DNB genes, Tgfb3 negatively regulated Mmp13 in the interaction path and they formed a bistable switching system from a dynamical perspective. In the in vitro study, Tgfb3 promoted fibrogenic genes and down-regulate Mmp13 gene transcription in an immortalized mouse HSC line JS1 and a human HSC line LX-2. The presence of a tipping point during liver fibrogenesis driven by DNB genes marks not only the initiation of significant fibrogenesis but also the repression of the scar resolution.


Subject(s)
Biomarkers/metabolism , Liver Cirrhosis/metabolism , Liver/metabolism , Matrix Metalloproteinase 13/metabolism , Transforming Growth Factor beta3/metabolism , Animals , Disease Models, Animal , Liver Cirrhosis/chemically induced , Liver Cirrhosis/genetics , Male , Matrix Metalloproteinase 13/genetics , Mice , Mice, Inbred C57BL , Thioacetamide/toxicity , Transforming Growth Factor beta3/genetics
5.
Clin Case Rep ; 8(12): 2377-2381, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33363745

ABSTRACT

In patients presenting with persistent anemia and gastric cardia telangiectasias, a potential etiology of portal hypertension due to chronic liver disease, especially primary biliary cirrhosis, should be considered. Drugs for treating specific liver disease and lowering portal hypertension are effective strategies to prevent hemorrhage.

6.
J Anim Sci ; 98(7)2020 Jul 01.
Article in English | MEDLINE | ID: mdl-32632450

ABSTRACT

Gut health is critically important for growing neonatal calves, and nutritional technologies are needed to prevent disease and stress challenges. Previous work feeding monensin (MON) in combination with an oregano, prebiotic, and cobalt-lactate (EOC) blend had demonstrated improved calf gut health and growth performance. The objective of this study was to evaluate the growth performance of calves fed MON and EOC alone or in combination. Eighty (80) newborn Holstein (37) female and (43) male calves were randomly assigned to one of four treatments arranged in a 2 × 2 factorial (MON and EOC). Treatments were: 1) Control: without MON or EOC added to the calf starter (CS); 2) MON: 50.8 mg/kg CS (Elanco, Greenfield, IN); 3) EOC: 44.1 mg/kg CS (Rum-A-Fresh, Ralco Inc. Marshall, MN); 4) MON + EOC: MON and EOC added to CS. Calves were fed colostrum followed by whole milk through weaning at 42 d, while CS was fed ad libitum through the 70-d experimental period. The MON by EOC interaction was found to be nonsignificant (P > 0.41) for growth performance. Calves fed without or with MON demonstrated similar (P > 0.70) body weight (BW; 68.7 and 68.9 kg without and with MON, respectively), while calves fed EOC demonstrated greater (P < 0.01) BW (67.3 and 70.4 kg without and with EOC, respectively) compared with calves fed without EOC. Calves fed a CS containing MON were similar (P > 0.47) in average daily gain (ADG; 0.88 and 0.91 kg/d) compared with calves fed without MON; however, feeding calves a CS with EOC increased (P < 0.01) ADG (0.84 and 0.95 kg/d) by 13% through the 70-d experimental period compared with calves not fed EOC. Frame measurements indicated that the greater ADG was due to increased (P < 0.10) frame growth for calves fed essential oils (EO) compared with calves fed without EO. A MON by EOC interaction (P < 0.01) for serum propionate concentration demonstrated calves fed MON + EOC and EOC were greater (P < 0.05) compared with calves fed Control, while calves fed MON were intermediate and different (P < 0.05). Feeding calves a CS with EOC increased (P < 0.04) immunoglobulin A, immunoglobulin G, and immunoglobulin M concentrations compared with calves fed without EOC. A MON by EOC interaction was detected (P < 0.01) for total tract starch digestibility for calves fed EOC or MON + EOC demonstrating greater (P < 0.05) starch digestibilities than Control-fed calves. These data demonstrate that EOC and MON fed in combination was not beneficial for enhancing the growth performance, but that calf growth performance can be improved with EOC compared with MON.


Subject(s)
Cattle/physiology , Cobalt/pharmacology , Diet/veterinary , Monensin/pharmacology , Origanum , Prebiotics , Animal Feed/analysis , Animal Nutritional Physiological Phenomena , Animals , Body Weight , Cobalt/administration & dosage , Colostrum , Female , Male , Milk , Monensin/administration & dosage , Oils, Volatile/administration & dosage , Oils, Volatile/pharmacology , Pregnancy , Starch
7.
World J Gastroenterol ; 25(43): 6440-6450, 2019 Nov 21.
Article in English | MEDLINE | ID: mdl-31798280

ABSTRACT

BACKGROUND: Serum amyloid A (SAA) is an acute phase protein mainly synthesized by the liver. SAA induces inflammatory phenotype and promotes cell proliferation in activated hepatic stellate cells, the major scar forming cells in the liver. However, few studies have reported on the serum levels of SAA in human liver disease and its clinical significance in various liver diseases. AIM: To investigate the serum levels of SAA in patients with different liver diseases and analyze the factors associated with the alteration of SAA levels in chronic hepatitis B (CHB) patients. METHODS: Two hundred and seventy-eight patients with different liver diseases and 117 healthy controls were included in this study. The patients included 205 with CHB, 22 with active autoimmune liver disease (AILD), 21 with nonalcoholic steatohepatitis (NASH), 14 with drug-induced liver injury (DILI), and 16 with pyogenic liver abscess. Serum levels of SAA and other clinical parameters were collected for the analysis of the factors associated with SAA level. Mann-Whitney U test was used to compare the serum SAA levels of patients with various liver diseases with those of healthy controls. Bonferroni test was applied for post hoc comparisons to control the probability of type 1 error (alpha = 0.05/6 = 0.008). For statistical tests of other variables, P < 0.05 was considered statistically significant. Statistically significant factors determined by single factor analysis were further analyzed by binary multivariate logistic regression analysis. RESULTS: All patients with active liver diseases had higher serum SAA levels than healthy controls and the inactive CHB patients, with the highest SAA level found in patients with pyogenic liver abscess (398.4 ± 246.8 mg/L). Patients with active AILD (19.73 ± 24.81 mg/L) or DILI (8.036 ± 5.685 mg/L) showed higher SAA levels than those with active CHB (6.621 ± 6.776 mg/L) and NASH (6.624 ± 4.891 mg/L). Single (P < 0.001) and multivariate logistic regression analyses (P = 0.039) for the CHB patients suggested that patients with active CHB were associated with an SAA serum level higher than 6.4 mg/L. Serum levels of SAA and CRP (C-reactive protein) were positively correlated in patients with CHB (P < 0.001), pyogenic liver abscess (P = 0.045), and active AILD (P = 0.02). Serum levels of SAA (0.80-871.0 mg/L) had a broader fluctuation range than CRP (0.30-271.3 mg/L). CONCLUSION: Serum level of SAA is a sensitive biomarker for inflammatory activity of pyogenic liver abscess. It may also be a weak marker reflecting milder inflammatory status in the liver of patients with CHB and other active liver diseases.


Subject(s)
Liver Diseases/blood , Serum Amyloid A Protein/metabolism , Adult , Biomarkers/blood , C-Reactive Protein/metabolism , Case-Control Studies , Chronic Disease , Female , Humans , Liver Abscess, Pyogenic/blood , Male , Middle Aged
8.
Life Sci ; 203: 39-47, 2018 Jun 15.
Article in English | MEDLINE | ID: mdl-29660433

ABSTRACT

BACKGROUND & AIM: Slit/Robo signaling was originally identified as a repulsive guidance cue in regulating axon branching and neuronal migration. Hepatic stellate cells (HSCs) are the key fibrogenic cells in the liver, which are migratory when activated, and express neural crest markers. The aim of the present study was to investigate the functional significance of Slit/Robo signaling in liver fibrogenesis and in HSCs. KEY FINDINGS: By transcriptomic analysis it was found that axon guidance signaling pathways were significantly upregulated in both diethylnitrosamine (DEN) and thioacetamide (TAA)-induced experimental liver fibrosis. The up-regulation of the ligand Slit2 and membrane receptor Robo2 genes within this pathway was further validated in TAA-induced fibrotic livers. By immunofluorescence staining, Robo2 was localized in fibrotic septa of fibrotic liver and on the surface of HSCs. By Western blot analysis, recombinant Slit2 (rSlit2) was found to promote fibrogenic protein expression in JS1 cells, an immortalized mouse HSC line, while activating PI3K/Akt signaling pathway. This effect was abrogated by LY294002, a PI3K/Akt pathway inhibitor. In addition, rSlit2 stimulation markedly inhibited JS1 cells migration in transwell migration assays, which was abrogated by small interfering RNA (siRNA) knockdown of Robo2 in the cells. SIGNIFICANCE: The present study provides evidence that Slit2/Robo2 signaling mediates the pathogenesis of hepatic fibrogenesis and regulates HSCs biology, thus providing potential markers for HSCs, and therapeutic and diagnostic target toward liver fibrosis.


Subject(s)
Cell Movement , Hepatic Stellate Cells/pathology , Intercellular Signaling Peptides and Proteins/metabolism , Liver Cirrhosis/pathology , Nerve Tissue Proteins/metabolism , Receptors, Immunologic/metabolism , Animals , Cell Adhesion , Cell Proliferation , Cells, Cultured , Hepatic Stellate Cells/metabolism , Liver Cirrhosis/metabolism , Male , Mice , Mice, Inbred C57BL , Signal Transduction
9.
Genet Test Mol Biomarkers ; 20(9): 535-43, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27391584

ABSTRACT

AIMS: To investigate the clinical and genetic risk factors associated with hepatocellular carcinoma (HCC) in cirrhotic patients with chronic hepatitis B (CHB). METHODS: Nine hundred forty-nine Chinese Han patients with CHB were studied, including noncirrhotic patients without HCC (N = 234), cirrhotic patients without (N = 281) and with HCC (N = 434). Patients were genotyped for 10 candidate single nucleotide polymorphisms (SNPs) by the polymerase chain reaction (PCR)-ligase detection reaction (LDR) method. RESULTS: By multivariate logistic regression analysis adjusted for Child-Pugh scores, noneffective antiviral treatment, drinking history, family history of HCC, and age ≥50 years old were associated with HCC risk (odds ratio [OR] = 5.923, 2.456, 2.241, 1.955, respectively). Sixty-two of 170 cirrhotic patients who achieved sustained virological suppression by antiviral treatment developed HCC, with fatty liver disease, family history of HCC, and family history of hepatitis B virus (HBV) infection as the risk factors (OR = 11.646, 3.339, 2.537, respectively). The SNPs associated with HCC risk in patients with cirrhosis and CHB were rs11536889 in TLR4 and rs2853744 in SPP1. Polymorphisms of TLR4 rs2149356, AP3S2 rs2290351, STXBP5L rs2169302, MLEC rs7976497, and SOCS3 rs4969168 were associated with HCC risk in specific stratified analyses with gender, age, and drinking history in the cirrhotic patients. CONCLUSIONS: Inadequate antiviral treatment, family history of HCC, drinking history, and age ≥50 years old are risk factors for HCC. Sustained suppression of HBV does not eliminate the risk of HCC. Specific host genetic factors may impact HCC development in Han Chinese cirrhotic patients with CHB, including SNPs in TLR4, SPP1, AP3S2, STXBP5L, MLEC, and SOCS3, which warrant further validation in additional cohorts.


Subject(s)
Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/virology , Hepatitis B, Chronic/pathology , Liver Cirrhosis/pathology , Liver Neoplasms/genetics , Liver Neoplasms/virology , Adult , Aged , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Female , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/genetics , Hepatitis B, Chronic/metabolism , Hepatitis B, Chronic/virology , Humans , Liver Cirrhosis/genetics , Liver Cirrhosis/metabolism , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Middle Aged , Odds Ratio , Polymorphism, Single Nucleotide , Risk Factors
10.
Zhonghua Gan Zang Bing Za Zhi ; 24(2): 152-6, 2016 Feb.
Article in Chinese | MEDLINE | ID: mdl-26983488

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most common cancer worldwide. Most of the HCC occur in developing countries. Chronic hepatitis B virus (HBV) infection is an important risk factor for HCC development. HBV induces immune-mediated chronic hepatitis, liver injury, regeneration and scar forming responses, leading to an inflammatory, fibrotic and immune deficient microenvironment. HBV may integrate into host genome, inducing genetic abnormality and altering the expression of HCC-related genes. HBV also expresses active proteins such as X (HBx) and S proteins, which may trans-activate HCC-related proteins expression, interact with intracellular specific proteins, activate a variety of signaling pathways, and induce aberrant epigenetic modifications. HBV mutation also has impact on HBV related HCC development.


Subject(s)
Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/virology , Hepatitis B, Chronic/pathology , Liver Neoplasms/pathology , Liver Neoplasms/virology , Epigenesis, Genetic , Hepatitis B virus , Humans , Mutation , Signal Transduction , Trans-Activators
11.
Article in English | MEDLINE | ID: mdl-26900402

ABSTRACT

BACKGROUND: Intact Toll-like receptor 4 (TLR4) has been identified in hepatic stellate cells (HSCs), the primary fibrogenic cell type in liver. Here, we investigated the impact of TLR4 signaling on the gene expression network of HSCs by comparing the transcriptomic changes between wild-type (JS1) and TLR4 knockout (JS2) murine HSCs in response to two TLR4 ligands, lipopolysacchride (LPS), or high-mobility group box 1 (HMGB1). RESULTS: Whole mouse genome microarray was performed for gene expression analysis. Gene interaction and co-expression networks were built on the basis of ontology and pathway analysis by Kyoto Encyclopedia of Genes and Genomes (KEGG). Gene expression profiles are markedly different between Wild type (JS1) and TLR4 knockout (JS2) HSCs under basal conditions or following stimulation with LPS or HMGB1. The differentially expressed genes between TLR4 intact and null HSCs were enriched in signaling pathways including p53, mTOR, NOD-like receptor, Jak-STAT, chemokine, focal adhesion with some shared downstream kinases, and transcriptional factors. Venn analysis revealed that TLR4-dependent, LPS-responsive genes were clustered into pathways including Toll-like receptor and PI3K-Akt, whereas TLR4-dependent, HMGB1-responsive genes were clustered into pathways including metabolism and phagosome signaling. Genes differentially expressed that were categorized to be TLR4-dependent and both LPS- and HMGB1-responsive were enriched in cell cycle, ubiquitin mediated proteolysis, and mitogen-activated protein kinase (MAPK) signaling pathways. CONCLUSIONS: TLR4 mediates complex gene expression alterations in HSCs. The affected pathways regulate a wide spectrum of HSC functions, including inflammation, fibrogenesis, and chemotaxis, as well as cell growth and metabolism. There are common and divergent regulatory signaling downstream of LPS and HMGB1 stimulation via TLR4 on HSCs. These findings emphasize the complex cascades downstream of TLR4 in HSCs that could influence their cellular biology and function.

12.
Gut ; 65(10): 1754-64, 2016 10.
Article in English | MEDLINE | ID: mdl-26045137

ABSTRACT

OBJECTIVE: We used an informatics approach to identify and validate genes whose expression is unique to hepatic stellate cells and assessed the prognostic capability of their expression in cirrhosis. DESIGN: We defined a hepatic stellate cell gene signature by comparing stellate, immune and hepatic transcriptome profiles. We then created a prognostic index using a combination of hepatic stellate cell signature expression and clinical variables. This signature was derived in a retrospective-prospective cohort of hepatitis C-related early-stage cirrhosis (prognostic index derivation set) and validated in an independent retrospective cohort of patients with postresection hepatocellular carcinoma (HCC). We then examined the association between hepatic stellate cell signature expression and decompensation, HCC development, progression of Child-Pugh class and survival. RESULTS: The 122-gene hepatic stellate cell signature consists of genes encoding extracellular matrix proteins and developmental factors and correlates with the extent of fibrosis in human, mouse and rat datasets. Importantly, association of clinical prognostic variables with overall survival was improved by adding the signature; we used these results to define a prognostic index in the derivation set. In the validation set, the same prognostic index was associated with overall survival. The prognostic index was associated with decompensation, HCC and progression of Child-Pugh class in the derivation set, and HCC recurrence in the validation set. CONCLUSIONS: This work highlights the unique transcriptional niche of stellate cells, and identifies potential stellate cell targets for tracking, targeting and isolation. Hepatic stellate cell signature expression may identify patients with HCV cirrhosis or postresection HCC with poor prognosis.


Subject(s)
Carcinoma, Hepatocellular , Extracellular Matrix Proteins/genetics , Hepatic Stellate Cells/physiology , Hepatitis C/complications , Liver Cirrhosis , Liver Neoplasms , Transcriptome/physiology , Animals , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/therapy , Disease Progression , Gene Expression Profiling/methods , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/etiology , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Mice , Prognosis , Rats , Recurrence , Risk Assessment/methods
13.
Sci Rep ; 5: 16278, 2015 Nov 05.
Article in English | MEDLINE | ID: mdl-26538132

ABSTRACT

Recent genome-wide associated studies (GWASs) have revealed several common loci associated with the risk of hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). We selected 15 single nucleotide polymorphisms (SNPs) identified through GWASs on HBV- or HCV-related HCC, and genotyped them in two independent Chinese cohorts of chronic HBV carriers, including 712 LC cases and 2601 controls. The association of each SNP with the risk of HBV-related LC was assessed by meta-analysis of the two cohorts. Of the 12 SNPs reported in HBV-related HCC GWASs, five SNPs (rs7574865 in STAT4, rs9267673 near C2, rs2647073 and rs3997872 near HLA-DRB1 and rs9275319 near HLA-DQ), were found to be significantly associated with the risk of HBV-related LC (rs7574865: P = 1.79 × 10(-2), OR = 1.17, 95% CI = 1.03-1.34; rs9267673: P = 4.91 × 10(-4), OR = 1.37, 95% CI = 1.15-1.63; rs2647073: P = 3.53 × 10(-5), OR = 1.63, 95% CI = 1.29-2.06; rs3997872: P = 4.22 × 10(-4), OR = 1.86, 95% CI = 1.32-2.62; rs9275319: P = 1.30 × 10(-2), OR = 1.32, 95% CI = 1.06-1.64). However, among the three SNPs associated with the risk of HCV-related HCC in previous GWASs, none of them showed significant association with the risk of HBV-related LC. Our results suggested that genetic variants associated with HBV-related hepatocarcinogenesis may already play an important role in the progression from CHB to LC.


Subject(s)
HLA-DQ Antigens/genetics , HLA-DRB1 Chains/genetics , Hepatitis B virus/metabolism , Liver Cirrhosis/genetics , Liver Cirrhosis/virology , Polymorphism, Single Nucleotide/genetics , STAT4 Transcription Factor/genetics , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/virology , Case-Control Studies , China , Female , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study/methods , Genotype , Hepatitis B, Chronic/genetics , Hepatitis B, Chronic/virology , Humans , Liver Neoplasms/genetics , Liver Neoplasms/virology , Male , Middle Aged , Risk
14.
Zhonghua Gan Zang Bing Za Zhi ; 23(7): 512-6, 2015 Jul.
Article in Chinese | MEDLINE | ID: mdl-26398842

ABSTRACT

OBJECTIVE: To identify risk factors of hepatocellular carcinoma (HCC) in cirrhotic patients with chronic hepatitis B (CHB). METHODS: A total of 715 cirrhotic patients with CHB were recruited from the Zhongshan Hospital Affiliated to Fudan University and enrolled in this case-control study between January 2009 and September 2014. All participants were Chinese Han residing in Shanghai and the surrounding areas. The patients were divided into a cirrhosis group (n =281) and a HCC group (n=434). History of hepatitis B infection and HCC, as well as clinical data from serological, imaging and pathological examinations were collected for analysis.SPSS software, version 19.0, was used for all statistical comparisons. RESULTS: Single factor analysis indicated that development of HCC in cirrhotic patients with CHB was significantly associated with male sex, age of 50 years or more, family history of HCC, alcohol consumption,fatty liver, detectable levels of hepatitis B virus (HBV) DNA, and history of HBV infection without effective antiviral treatment. Multivariate logistic regression analysis indicated that age of 50 years or more (P =0.005, odds ratio [OR] =1.766), history of alcohol consumption (P =0.002, Or = 2.570), family history of HCC (P =0.014, Or = 2.268), fatty liver (P =0.023, Or = 3.390), and history of HBV infection without effective antiviral treatment (P < 0.001,Or = 5.389) were risk factors of HCC.The risk factors for development of HCC in cirrhotic patients with hepatitis B after achieving sustained virologic suppression (SVS) were family history of HBV infection (P =0.014, Or = 2.537), family history of HCC (P =0.037,Or = 3.339) and fatty liver (P =0.018, Or = 11.646). CONCLUSION: Risk factors of HCC in cirrhotic patients with CHB include age,drinking history,family history of HCC, fatty liver, and ineffective antiviral treatment of CHB.Family history of HBV infection or HCC, and fatty liver disease, were significantly associated with HCC development after SVS in patients with hepatitis B-related cirrhosis.


Subject(s)
Carcinoma, Hepatocellular , Hepatitis B, Chronic , Liver Cirrhosis , Liver Neoplasms , Alcohol Drinking , Antiviral Agents , Case-Control Studies , China , Fatty Liver , Hepatitis B virus , Humans , Male , Odds Ratio , Risk Factors
15.
World J Gastroenterol ; 21(13): 3860-6, 2015 Apr 07.
Article in English | MEDLINE | ID: mdl-25852270

ABSTRACT

Chronic hepatitis B virus (HBV) infection is a critical risk factor for the carcinogenesis and progression of hepatocellular carcinoma (HCC). It promotes HCC development by inducing liver fibrogenesis, genetic and epigenetic alterations, and the expression of active viral-coded proteins. Effective antiviral treatments inhibit the replication of HBV, reduce serum viral load and accelerate hepatitis B e antigen serum conversion. Timely initiation of antiviral treatment is not only essential for preventing the incidence of HCC in chronic hepatitis B patients, but also important for reducing HBV reactivation, improving liver function, reducing or delaying HCC recurrence, and prolonging overall survival of HBV-related HCC patients after curative and palliative therapies. The selection of antiviral drugs, monitoring of indicators such as HBV DNA and hepatitis B surface antigen, and timely rescue treatment when necessary, are essential in antiviral therapies for HBV-related HCC.


Subject(s)
Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Hepatitis B virus/drug effects , Hepatitis B, Chronic/drug therapy , Liver Neoplasms/drug therapy , Animals , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/virology , Hepatitis B virus/growth & development , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/mortality , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/virology , Neoplasm Recurrence, Local , Risk Factors , Time Factors , Treatment Outcome , Virus Activation/drug effects
16.
Zhonghua Gan Zang Bing Za Zhi ; 21(4): 275-8, 2013 Apr.
Article in Chinese | MEDLINE | ID: mdl-24021789

ABSTRACT

OBJECTIVE: To investigate the effects of cordyceps acid and cordycepin on the inflammatory phenotype and fibrogenic property of hepatic stellate cells (HSCs). METHODS: An immortalized mouse HSC line (JS1) was stimulated with lippolysaccharide (LPS; 100 ng/ml) to induce an inflammatory response with or without co-administration of cordyceps acid or cordycepin in various concentrations (10, 50, or 200 mumol/L). Effects of the treatments on the chemokine monocyte chemotactic protein-1 (MCP-1) mRNA expression in the cells and the protein secretion in the cell culture supernatants were determined by reverse transcription and real-time quantitative PCR (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. In addition, JS1 cells were treated with transforming growth factor-b1 (TGFb1; 10 ng/ml) to induce a fibrogenic response with or without co-administration of cordyceps acid or cordycepin in various concentrations (10, 50, or 200 mumol/L). Effects on the expression of fibrogenic proteins including collagen type I and a-smooth muscle actin (a-SMA), were investigated by Western blot. RESULTS: High-concentration (200 mumol/L) treatments of both cordyceps acid and cordycepin significantly inhibited the LPS-induced up-regulation of MCP-1 transcription and secretion (mRNA: 2.07 +/- 0.29 vs. 3.35 +/- 0.26, t = 15.90 and 1.15 +/- 0.23 vs. 4.17 +/- 0.61, t = 8.93; protein: 1.88 +/- 0.06 vs. 2.33 +/- 0.06, t = 10.39 and 1.47 +/- 0.25 vs. 1.97 +/- 0.04, t = 4.60; all P less than 0.05). All concentrations of cordyceps acid and cordycepin inhibited the TGFb1-induced up-regulation of collagen type I and a-SMA protein expression. However, the effects were more robust with the 200 mumol/L concentrations (P less than 0.05). CONCLUSION: Cordyceps acid and cordycepin ameliorate the LPS-induced inflammatory phenotype and TGFb1-induced fibrogenic response of cultured HSCs. These effects may contribute significantly to the drugs' therapeutic mechanisms to inhibit and resolve liver fibrosis.


Subject(s)
Cordyceps , Hepatic Stellate Cells , Animals , Cells, Cultured , Chemokine CCL2/metabolism , Hepatic Stellate Cells/metabolism , Transforming Growth Factor beta1/metabolism , Up-Regulation/drug effects
17.
Genet Test Mol Biomarkers ; 17(9): 681-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23844940

ABSTRACT

BACKGROUND AND AIMS: Recently, genetic association studies have linked a number of single nucleotide polymorphisms (SNPs) with liver fibrosis risk of hepatitis C. The present study was designed to validate the association of emerging SNPs with development of liver cirrhosis and chronicity in a Chinese population infected with hepatitis B virus (HBV). METHODS: 714 Chinese subjects with persistent HBV infection (429 with evident liver cirrhosis and 285 without cirrhosis clinically or pathologically) and 280 subjects with spontaneous HBV clearance were studied. Six SNPs in five candidate genes were detected with the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) method. The distribution of each polymorphism was compared between the age-matched cirrhotic and noncirrhotic subjects, and between subjects with persistent infection and spontaneous HBV clearance. RESULTS: The rs2679757 polymorphism of antizyme inhibitor 1 (AZIN1) gene was associated with the risk of cirrhosis (odds ratio [OR] for GG+AG versus AA=1.47, 95% confidence interval [CI]=1.08-2.01, p=0.01). So was rs886277 in the transient receptor potential cation channel subfamily M, member 5 (TRPM5) gene (OR for CC versus CT+TT=1.63, 95% CI=1.20-2.22, p=0.002). The frequencies of these two SNPs were also associated with the severity of decompensated cirrhosis based on the Child-Pugh classification. Genotype frequencies of other SNPs were not different between the cirrhotic and noncirrhotic groups. No SNPs were associated with the outcome of spontaneous HBV clearance. CONCLUSIONS: AZIN1 rs2679757 and TRPM5 rs886277 are associated with the risk of HBV-related liver cirrhosis in Chinese. The emerging SNPs warrant further clinical validation in other cohorts or ethnic groups, and could lead to mechanistic studies to reveal their contributions to fibrosis progression.


Subject(s)
Carrier Proteins/genetics , Genotype , Hepatitis B/genetics , Liver Cirrhosis/genetics , Polymorphism, Single Nucleotide , TRPM Cation Channels/genetics , Asian People , China/epidemiology , Female , Hepatitis B/complications , Hepatitis B/epidemiology , Hepatitis B/pathology , Humans , Liver Cirrhosis/epidemiology , Liver Cirrhosis/etiology , Liver Cirrhosis/pathology , Male , Risk Factors
18.
Curr Pharm Des ; 19(7): 1262-72, 2013.
Article in English | MEDLINE | ID: mdl-23092345

ABSTRACT

MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy.


Subject(s)
Carcinoma, Hepatocellular/genetics , Gene Expression , Liver Diseases/genetics , Liver Neoplasms/genetics , MicroRNAs/genetics , Carcinoma, Hepatocellular/diagnosis , Humans , Liver Neoplasms/diagnosis
20.
Zhonghua Gan Zang Bing Za Zhi ; 20(8): 581-4, 2012 Aug.
Article in Chinese | MEDLINE | ID: mdl-23207150

ABSTRACT

To determine the potential of the high mobility group box-1 protein 1 (HMGB1) to activate Toll-like receptor 4 (TLR4) signaling in hepatic stellate cells (HSCs) and investigate the subsequent transition of HSC towards the inflammatory phenotype. Three immortalized mouse HSC cell lines, wild-type (JS1), TLR4-/- (JS2) and MyD88-/- (JS3), were subcultured in plates and divided into groups of normal control (untreated), postive control (lipopolysaccaride, LPS treatment), and experimental (HMGB1 treatment). All groups were transfected with luciferase reporter plasmids carrying responsive elements for either the nuclear factor-kappa B (NF-kB) or activator protein-1 AP-1 transcription factors. Following stimulation with normal saline, LPS (100 ng/mL) or HMGB1 (100 ng/mL), the activation of NF-kB or AP-1 was detected by a dual-luciferase reporter assay system. The induction of monocyte chemotactic protein-1 (MCP-1) transcription was determined by measuring the mRNA levels using real time quantitative reverse transcription PCR (qRT-PCR). The secreted protein levels of MCP-1 were determined by enzyme-linked immunosorbent assay (ELISA) of the culture supernatants. Activation of NF-kB- and AP-1-responsive reporters was significantly up-regulated in JS1 cells treated with HMGB1 or LPS, and the activation was coincident with markedly up-regulated transcription and secretion of MCP-1. However, HMGB1 and LPS treatment produced no responsive of the NF-kB and AP-1 reporters, and no increase in expression or secretion of MCP-1, in JS2 or JS3 cells. As an endogeous ligand of TLR4, HMGB1 may activate TLR4 signaling and the TLR4-mediated inflammatory response of HSC.


Subject(s)
HMGB1 Protein/pharmacology , Hepatic Stellate Cells/metabolism , NF-kappa B/metabolism , Toll-Like Receptor 4/metabolism , Transcription Factor AP-1/metabolism , Animals , Cell Line , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Gene Knockout Techniques , Hepatic Stellate Cells/drug effects , Lipopolysaccharides/pharmacology , Mice , NF-kappa B/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction/drug effects , Toll-Like Receptor 4/genetics , Transcription Factor AP-1/genetics , Transfection , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...